The sooner dairy companies have probiotics with independent intellectual property rights, the better

" dairy enterprises to seize the opportunity of history, from the intestinal science to start. Starting with intestinal science, our brands and international brands can be on the same starting line. Liu Xiaojun, president of Coto Bio, said at the 3rd China Dairy Capital Forum held on October 30.As an important grasper of intestinal health, Liu Xiaojun in the day's theme speech, in-depth and shallow for the participants to introduce the important role of probiotics and the future market prospects, but also put forward that dairy enterprises should pay full attention to the value of having independent intellectual property rights bacteria, "the sooner the better, who can do who can stand on the commanding heights." " dairy companies should create probiotics with independent property rights the intestine is recognized as the gateway to human health, and the health of the intestine is closely related to the gut bacteria. As one of the densest micro-ecosystems on earth, intestinal bacteri groups are the fate community of human nutrition, which can lead to chronic diseases, metabolic diseases, eating diseases and nutritional diseases if dysfunctional." is very important to maintain the health of the gut bacteria. Liu Xiaojun Dao, "targeting intestinal flora can prevent disease and promote health, common drug therapy and nutritional interventions beneficial bacteria, probiotics, including hospital faeces transplantation, plant extraction, etc., but the most direct effect on intestinal health, the best effect, the most comprehensive or probiotics." " dairy products are excellent carriers of probiotics." Probiotics are mostly entered into the body through media such as food and beverages, and probiotics carried through dairy products are more conducive to survival or metabolism. Liu Xiaojun said.the same is true, he is very optimistic about the market growth potential of functional dairy products. Statistics show that China is now the world's second largest functional food market, the market size is expected to exceed 800 billion yuan to 100 billion yuan by 2030. Functional dairy as a pioneer of functional food, through the consumption of dairy products to improve health of consumers are increasing." for example, want to improve your child's appetite, ensure nutritional intake and physical development, through drinking dairy products containing probiotics can be achieved. Young people overeating and eating irregularly are prone to indigestion, and can also develop probiotic dairy products that promote intestinal well-being and rejuvenation to improve regulation.It is understood that the world's dairy-related dairy enterprises and food enterprises such as Nestle, Danon, nutrients, etc., will be the core of their entire health strategy, because they started early research and development, now has an excellent independent intellectual property strains, and year-on-year continue to invest a lot of energy and cost in the field of probiotics to research, excavate the function of probiotics, increase its scientific endorsement and application value." worldwide study of intestinal bacteria continues to heat up, with only 300 articles related to guts and bacteria in 2003 and an estimated 20,000 by this year. "Liu Xiaojun believes that the future development of any industry must be scientific first, and the rise of intestinal and intestinal bacterial group research heat, will greatly broaden the application of related products, the development of the entire industry to form a comprehensive good.", China's dairy companies should follow the trend and press ahead with research and development of strains with independent intellectual property rights. "At present, none of the strains with independent intellectual property rights of Chinese dairy enterprises can be included in the national list of edible strains of infants and young children and the list of health care products. Be sure to seize this opportunity, because probiotics take a long time to research, not that you hit 200 million today, tomorrow will have results. He said, "Whoever succeeds and enters this list will be able to gain a strategic advantage by standing on the commanding edge and having a say." Koto Bio has built Asia's largest library of bacteria innovative research and development to continuously build the value of strains as just successfully listed in China's A-share GEM probiotic first share, Koto Bio in the research and development of independent intellectual property probiotics and industrialization on the road, has been a step ahead.It is understood that after the creation of Coto Bio, the germ program was launched, along the ancient trade routes and fermented milk transmission channels carried out a global collection, separation and protection of strains, aimed at collecting and protecting lactic acid bacteria resources. In the past 20 years, Koto bio from the original pollution-free areas of natural fermented food, baby faeces, breast milk, isolated, collected and maintained more than 20,000 strains of lactic acid bacteria (including probiotics), built China and even Asia's largest lactic acid bacteria resource bank."Only by building a library can we find good and good strains." For example, ethnic minority areas, many herders have gone to urban life, ancestral generations left natural fermentation milk do not do, inside the rich and valuable bacterial resources will completely disappear. And we've kept valuable germ resources for later development and utilization. Self-made strains like Mengniu, Jiang zhong, and small sunflowers are screened from our library. Liu Xiaojun said, "Our goal is to build the world's largest lactic acid bacteria resource bank in the future." ", Koto Bio also relies on a strong library of strains for scientific screening and functional evaluation of potential target strains." From artificial digestion, safety evaluation, genetic background to functional research, processing special selection, probiotics good or bad, in fact, there are three characteristics: first, there are no good strains, second, there is no good processing technology, the third is whether there is no through a large number of clinical (human) tests, scientific evidence-based efficacy results. He said.it is understood that in recent years, Koto Bio has invested a great deal of money and carried out 37 clinical studies, including research on upper respiratory tract infections in middle-aged and elderly people, polycystic ovary syndrome in women, type 2 diabetes, cancer immunotherapy, etc. Among them, in terms of intestinal health, in 2018, Koto Bio has launched the Chinese Intestinal Microbiology System Research Project in Huairou Science City, Beijing, in cooperation with a number of universities and scientific research institutions, through the establishment of a database of Chinese intestinal bacteri, and constantly excavate and expand probiotics suitable for the Chinese intestinal virlobes, screening for new probiotics with personalized and precise intervention." solid foundation research is the soul of enterprise innovation, but also for customers to innovate product development source. Liu Xiaojun stressed, "We need to constantly upgrade the methods and techniques of research, and continue to build the value of strains." That'